p185 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease | Zendy

Olaf Reich | Zendy; Bernadette Liegl | Zendy; Karl Tamussino | Zendy; Sigrid Regauer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

p185 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease

Author(s) -

Olaf Reich,

Bernadette Liegl,

Karl Tamussino,

Sigrid Regauer

Publication year - 2004

Publication title -

modern pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.596

H-Index - 153

eISSN - 1530-0285

pISSN - 0893-3952

DOI - 10.1038/modpathol.3800243

Subject(s) - oncogene , vulva , medicine , fluorescence in situ hybridization , pathology , gene duplication , disease , biology , gene , cancer , biochemistry , cell cycle , chromosome

We evaluated p186Her2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease. We identified six patients with recurrent vulvar Paget's disease in our archives. The number of recurrences ranged from 1 to 11 over a time period of 1-168 months. Recurrences were evaluated immunohistochemically for p185Her2 overexpression with the HercepTest and for HER2 oncogene amplification with fluorescence in situ hybridization. p185Her2 overexpression was scored as 3 in two patients, as 2 in two patients, and as 1 in two patients. All patients with scores 2 and 3 showed HER2 oncogene amplification. Overexpression of p185Her2 and HER2 oncogene amplification appears to be common in recurrent vulvar Paget's disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research